Horizon Pharma Willing to Sweeten Proposal If Depomed Talks

Updated on

Horizon Pharma Plc told Depomed Inc. that it’s prepared to increase its $2 billion offer for the company and include a cash component of as much as 25 percent of the deal -- if Depomed comes to the negotiating table.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.